Latest news with #Alzheimer'sdisease
Los Angeles Times
03-07-2025
- Health
- Los Angeles Times
‘Chaotic and deeply frightening': Once a global gold standard, U.S. government health guidance is falling apart
Weeks after President Trump took office, multiple government webpages referencing gender and sexual orientation abruptly disappeared from the internet. Many returned after a February court order. But they came with an unusual addition: a disclaimer from the Department of Health and Human Services denying facts provided by its own agencies. 'Any information on this page promoting gender ideology is extremely inaccurate and disconnected from the immutable biological reality that there are two sexes, male and female,' reads a statement now appended to several government webpages, including some discussing HIV, civil rights protections and healthcare for transgender people. 'This page does not reflect biological reality and therefore the Administration and this Department rejects it.' Once a global leader in public health guidance, the U.S. government is now embarking on the unusual project of denying or deleting once-public information provided by its own researchers. The U.S. Global Change Research Program's entire website went dark Monday, taking with it an extensive report on the health effects of climate change whose authors included employees of the Centers for Disease Control and Prevention, the Occupational Safety and Health Administration and other government agencies. Dozens of research databases maintained by the National Institutes of Health on topics such cancer and Alzheimer's disease now display a warning that they are 'under review for potential modification in compliance with Administration directives.' Some federal sites have added new pages that at times contradict evidence-based guidance posted on the same site. currently hosts both a recent presentation by vaccine skeptic Lyn Redwood about the dangers of the preservative thimerosal, as well as a fact sheet published in December debunking many of the incorrect statements about thimerosal that anti-vaccine campaigners have advanced. (The site also notes that thimerosal was removed from U.S. childhood vaccines in 2001.) The consequence, physicians and child health advocates said this week, is having fewer tools to help healthcare providers and the public make informed decisions, further eroding the public's trust in science. 'Use whatever analogy you want to use — this is a five-alarm fire,' said Dr. Sean O'Leary, a pediatric infectious-disease specialist who chairs the American Academy of Pediatrics' infectious-disease committee. 'One day the information is there, and the next day it's gone. And it's being driven purely by politics and not by science. It's dystopian, frankly,' O'Leary said. 'The CDC is a model for the world in terms of what they do for the U.S. population, and that is being harmed in a very profound way.' O'Leary was one of several physicians The Times spoke with who stressed that the contradictory messages emerging from U.S. government agencies were not a sign of a fracturing consensus among public health professionals, but of the administration's turn away from those professionals' expertise. The nation's various scientific societies, professional groups and medical associations 'are all in alignment,' O'Leary said. 'There is no disagreement among us that what is happening is chaotic and deeply frightening for the American people.' For the first time since the 1990s, the American Academy of Pediatrics no longer endorses the CDC's childhood vaccination schedule. Visitors to the academy site are directed not to the CDC's most recent guidelines, which no longer suggest outright that children get the COVID-19 vaccine, but to a version published in November that retains the recommendation that it be given only to children 6 months and older. After the CDC's Advisory Committee on Immunization Practices voted last month to recommend only thimerosal-free flu shots and drop COVID vaccine recommendations for healthy pregnant people without the scientific input the group typically receives before such decisions, both the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists issued statements denouncing the committee's recommendations. (Roughly 96% of the flu shots administered last year did not contain thimerosal, according to the CDC.) The CDC now deems the COVID shot a 'shared clinical decision-making vaccination' for children. Unlike routine or risk-based vaccine recommendations, this designation is 'individually based and informed by a decision process between the health care provider and the patient or parent/guardian,' according to But by depleting and muddying the information it makes publicly available, the administration is depriving parents of the evidence-based data they need to make responsible decisions, said Bruce Lesley, president of the child health-advocacy group First Focus on Children. 'We all should rely on some sort of expertise and protections,' Lesley said. 'There's no way to be able to put that burden on parents and to expect that it's just going to be all fine.' The CDC website in particular has long been a resource that physicians and other healthcare providers rely on to stay abreast of evidence-based recommendations for treatment and emerging health trends around the country, doctors said. 'What all this is doing is causing a great deal of confusion, and not just for our families and our patients, but also for our providers and our doctors,' said Dr. Eric Ball, an Orange County pediatrician and the American Academy of Pediatrics' California chair. 'We rely on accurate information from our public health sources so that we can help best take care of our patients, and when we can't trust those sources, that makes it more difficult for us to do our jobs and endangers the health of our communities.' Since Trump took office, several independent efforts have sprung up to archive what data can be saved from government websites before its withdrawn or deleted, such as the Data Rescue Project and But the patchwork of alternatives can't replace what has long been for the U.S. public — a single-stop clearinghouse for evidence-based information presented in plain language, said Dr. Tina Tan, a professor of pediatrics at Northwestern University's Feinberg School of Medicine and the president of the Infectious Diseases Society of America. 'The question now is who do you trust, and where do you get trusted information? And that's a major issue,' Tan said. 'The American public needs to understand that all these changes are going to have some type of impact on them.'
Time of India
24-06-2025
- Health
- Time of India
Top neurosurgeon shares tips to boost memory and improve focus naturally
Dr. Arun L. Naik highlights the importance of acetylcholine for memory and focus. He suggests boosting it naturally through adequate sleep, mental stimulation, and mindfulness practices. Dietary changes, including consuming eggs, nuts, fatty fish, and leafy greens, can also help maintain healthy acetylcholine levels, enhancing cognitive performance and mental clarity. Keeping the brain in the best shape is crucial for overall health and wellness. In today's time, where many are overwhelmed with work and personal responsibilities, being forgetful and losing focus has become increasingly common. Dr. Arun L. Naik, a leading neurosurgeon trained at All India Institute of Medical Sciences (AIIMS), New Delhi, has now shared some science-backed tips to stay sharp and focused. The neurosurgeon says that the key to sharper memory and improved focus lies in one powerful neurotransmitter, acetylcholine. What is acetylcholine Acetylcholine is a neurotransmitter that acts as a communication bridge between neurons. It acts as a chemical messenger that transmits signals between nerve cells and from nerves to muscles. From voluntary muscle movement to complex brain functions such as memory and attention, this neurotransmitter influences nearly every part of the nervous system. Low acetylcholine levels can lead to forgetfulness, difficulty concentrating, and even muscle weakness. Conditions like Alzheimer's disease are linked to acetylcholine deficits. 'As we age, acetylcholine levels can decline, particularly in neurodegenerative conditions like Alzheimer's disease, where the cholinergic system is one of the first to deteriorate. This has led to the use of acetylcholinesterase inhibitors (like donepezil) in treatment, aimed at increasing available acetylcholine in the brain,' the surgeon wrote in a post shared on Instagram. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trending in in 2025: Local network access control [Click Here] Esseps Learn More Undo The key is to boost acetylcholine to enhance cognitive performance and mental clarity. The neurosurgeon has shared some tips on how simple lifestyle changes and dietary choices can help you maintain healthy levels without medication. Let's take a look. How to naturally boost acetylcholine Certain lifestyle changes can help boost acetylcholine. Dr. Naik has suggested making the following changes. Adequate sleep: It is important to prioritize sleep. A good night's rest can help the brain produce acetylcholine. Aim for at least 7–8 hours of quality sleep every night. Mental stimulation: To keep the brain sharp, it is important to challenge it. Engage the brain with activities like puzzles, chess, or reading, which strengthen neural connections and support acetylcholine activity. Learning a new skill, like playing an instrument, can also help Mindfulness: Managing stress is important to keep the brain healthy, as chronic stress depletes acetylcholine. Practicing mindfulness techniques, such as meditation, yoga, or deep breathing. Such practices can lower stress hormones and protect the brain's neurotransmitter balance. What are acetylcholine-rich foods Diet plays a pivotal role in acetylcholine production. Choline, a nutrient found in certain foods, is the building block for this neurotransmitter. The neurosurgeon has recommended adding these acetylcholine-friendly foods into your diet. Eggs: Egg yolks are great source of choline. A single egg provides about 169 mg of choline. This means eating just 2 eggs per day covers 61% of the DV. Nuts and seeds: Eating almonds and flaxseeds can help. Have a small handful of these nuts regularly Fatty fish: Good news for pescatarians. Salmon and other fatty fish are good for the brain. These fish provide omega-3 fatty acids, which enhance acetylcholine function and reduce brain inflammation. Aim for two servings per week. Leafy greens: Eat your greens. Spinach and kale are loaded with nutrients that support the production of the neurotransmitter. These greens also provide antioxidants that protect brain cells. One step to a healthier you—join Times Health+ Yoga and feel the change
Euronews
04-06-2025
- Business
- Euronews
Bulgaria to adopt the euro as ECB and EU Commission give green light
Bulgaria will join the eurozone at the start of next year after clearing a series of economic hurdles, securing approval from the European Central Bank and the European Commission on Wednesday. "Today's report is a historic moment for Bulgaria, the euro area and the European Union," said EU economy chief Valdis Dombrovskis. ECB Executive Board Member Philip Lane noted: "I wish to congratulate Bulgaria on its tremendous dedication to making the adjustments needed." Since it joined the EU in 2007, Bulgaria has been seeking to switch its current currency, the lev, to the euro — although persistent inflation and political unrest have stalled progress. Last year, Bulgaria's accession to the eurozone was pushed back as the country failed to contain price pressures. These shot up during Europe's energy crisis following Russia's invasion of Ukraine, although annual CPI cooled to 3.5% in April, close to the EU's 3% target. The ECB and the Commission are now satisfied that economic criteria are fulfilled, notably relating to the public debt and deficit, inflation, interest rates and the exchange rate. Bulgaria's accession must now be approved by euro area finance ministers, with the final go-ahead expected on 8 July. Wednesday's breakthrough came after a wave of protests in Bulgaria against the adoption of the euro. Disinformation campaigns from home and abroad have made certain groups fearful of the change, notably pushing narratives that the euro will worsen poverty and stoke inflation. Bulgarian President Rumen Radev encouraged the anti-euro voices by proposing earlier this month a referendum on the currency. The proposal was rejected by the pro-European majority in parliament, which accused Radev of acting in favour of Moscow with his last-minute attempt to sabotage the euro adoption. Countries that have previously joined the eurozone have seen modest inflationary spikes. Even so, eurozone membership also offers a series of benefits as it reduces borrowing costs, attracts foreign investment, and facilitates cross-border trade. A position in the eurozone would also allow Bulgaria to have a greater say over the ECB's monetary policy trajectory. Croatia was the last country to join the eurozone in 2023. Neurological conditions affected more than 3 billion people worldwide in 2021, according to a major study published in The Lancet in 2024. These conditions impact the nervous system and comprise a wide variety of disorders, including epilepsy, Alzheimer's disease, Parkinson's disease, dementia and many others. Today, neurological diseases are the leading cause of illness and disability worldwide, and beyond the toll they take on patients and their loved ones, they also impose a significant economic burden. According to another study published in The Lancet, brain disorders are projected to cost the global economy 16 trillion dollars between 2010 and 2030, a figure largely driven by the early onset of these conditions and the resulting long-term loss of productivity. Given the need for research and treatment of brain disorders, some companies are investing in this area to advance our understanding of the brain. Among the most high-profile is Neuralink, founded by Elon Musk in 2016. However, Europe has also emerged as a powerhouse in neurotechnology. A notable example is the Spanish company Neuroelectrics, launched by Ana Maiques and Giulio Ruffini in 2011. Over the years, Neuroelectrics has expanded from its European roots to establish a presence in the United States, becoming an international leader in the field. Ana Maiques, CEO of Neuroelectrics, joined My Wildest Prediction to share her boldest insights and vision for the future of brain technology. My Wildest Prediction is a podcast series from Euronews Businesswhere we dare to imagine the future with business and tech visionaries. In this episode, Tom Goodwin talks to Ana Maiques, CEO and Co-Founder of Neuroelectrics. 'My wildest prediction is that neurotechnology is going to impact our daily lives in ways we cannot even imagine,' Ana Maiques told Euronews Business. Maiques clarified that neurotechnology tools should and will not be used to enhance individual traits such as intelligence or reverse ageing. However, she believes these tools will be applied to treat medical conditions, broaden people's experience of reality and strengthen our general understanding of how the brain works. 'A lot of people approach us! (...) We have a paper written with Refik Anadol where we monitored the impact on the visitors' brains of his AI-generated sculptures. Now, we are talking with Michelin-star chefs who want to study the impact of food on the brain from a scientific perspective,' she explained. Maiques acknowledged the fears some people have about using electricity in the brain but emphasised that much of this concern stems from a lack of understanding of the real, positive impact neurotechnology can have. Unlike Neuralink, which develops in-brain implants, Neuroeletrics takes a non–invasive approach, using external tools to monitor and interact with the brain. Neuroelectrics' standout product is the Neoprane Headcap. The cap features electrodes connected to a wireless module located in the back. These electrodes can both monitor the brain activity and deliver electrical stimulation. This tool can help diagnose sleep disorders, epilepsy, and other neurological conditions. It is especially useful in hospital settings where electroencephalogram (EEG) equipment may not be available or where technicians are not present. To develop these tools, Neuroelectrics has been using machine learning and AI for years. 'There is no way we can, as humans, decode the brain without the help of these kinds of tools,' Ana Maiques said. The CEO noted that advancements in AI could lead to the potential modelling of the brain, raising many ethical and scientific questions. However, she emphasised the importance of continued experimentation, as achieving a complete scientific understanding of the brain remains highly complex.
Miami Herald
13-05-2025
- Health
- Miami Herald
Morehouse College names new president
Courtesy: Morehouse College The Morehouse College Board of Trustees has named renowned public health leader and biostatistician Dr. F. DuBois Bowman, a 1992 graduate of Morehouse, as the College's 13th president following a national search. Dr. Bowman will assume the role on July 15, 2025, succeeding President David A. Thomas, who concludes his tenure in June. Dr. Bowman currently serves as dean of the University of Michigan School of Public Health and holds the Roderick J. Little Collegiate Professorship of Biostatistics. A nationally respected scholar, innovator, and academic leader, Bowman is a member of the National Academy of Medicine, a fellow of the American Statistical Association, and a fellow of the American Association for the Advancement of Science. 'Dr. Bowman's record of visionary leadership, his deep commitment to academic excellence, and his lifelong dedication to Morehouse make him the ideal choice to lead the College into its next era,' said Willie Woods '85, chairman of the Morehouse College Board of Trustees. 'He brings an extraordinary blend of intellectual rigor, strategic thinking, and values-driven leadership.' A leading expert in the statistical analysis of complex data sets, Dr. Bowman's research has transformed understanding of neurological and mental health disorders such as Parkinson's disease, Alzheimer's disease, depression, and schizophrenia. His work has shaped more personalized therapeutic approaches and has explored how environmental factors affect brain function in youth. At the University of Michigan, Dr. Bowman leads a top-ranked school of public health with more than 1,300 students and an annual sponsored research portfolio exceeding $100 million. He has launched interdisciplinary initiatives to address public health challenges, such as firearm injury prevention, health equity, and infectious disease control. His leadership has fostered a culture of inclusion, innovation, and service across the school. A proud Morehouse alumnus, member of Phi Beta Kappa, and Omega Psi Phi Fraternity, Inc., Dr. Bowman has remained closely connected to his alma mater as a two-time Morehouse parent and a dedicated mentor, facilitating a University of Michigan pipeline program for students from Morehouse and Spelman colleges. In 2019, he was awarded the College's highest award for alumni – the Bennie Trailblazer Award –named after the sixth president of the College, Dr. Benjamin Elijah Mays. 'Returning to Morehouse as its 13th president is the honor of a lifetime,' said Dr. Bowman. 'This institution shaped who I am-instilling a commitment to excellence, justice, and impact. I am excited to partner with faculty, staff, students, alumni, and supporters to build on our legacy and write the next chapter of Morehouse's transformative story.' His appointment follows a historic milestone for the College, which was recently named both a Research College & University (RCU) and Opportunity College & University (OCU) in the 2025 Carnegie Classifications. The dual designation reflects Morehouse's growing investment in research and its enduring mission to provide students from underrepresented communities with access to life-changing education and competitive post-graduate outcomes. Prior to his deanship at Michigan, Dr. Bowman held academic and leadership positions at Columbia University and Emory University. He earned a Master of Science in Biostatistics from the University of Michigan and a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill. Dr. Bowman is married to Cynthia Bowman who holds degrees from Spelman College, Georgia Tech, and Northwestern. They have four children, including a son who graduated from Morehouse in 2024 and a younger son who is currently enrolled at the College. The post Morehouse College names new president appeared first on HBCU Gameday. Copyright HBCU Gameday 2012-2025
Yahoo
24-03-2025
- Health
- Yahoo
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference
Multiple datasets support continued development of ProMIS' antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced plans to deliver virtual oral presentations at the 2025 Alzheimer's and Parkison's Disease (AD/PD) International Conference taking place in Vienna, Austria from April 1 - 4, 2025. The oral presentations are available on demand starting on Tuesday, April 1, 2025 at 7:00am C.E.T (2:00am E.T). 'We are pleased to demonstrate the potential of our computational modeling platform in the development of next-generation antibodies and targeted vaccines for neurodegenerative diseases such as AD, PD and ALS,' said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. 'These promising preclinical data may support vaccination with our platform-derived epitopes and selective antibody targeting of misfolded toxic aggregates of TDP-43 as a potentially safe and effective method to treat neurodegenerative diseases. We look forward to sharing these data at the upcoming AD/PD 2025 International Conference.' Presentation details Title: Rational Design of Alzheimer's Vaccine to Maximize Selective Targeting of Toxic Amyloid-Beta Oligomers Presenter: Johanne Kaplan, Chief Development Officer, ProMIS Neurosciences Abstract Number: 1321 A large body of evidence indicates that soluble toxic oligomers of amyloid-beta (AβO) are a primary driver of AD. Through computational modeling, four different conformational B cell epitopes of AβOs were identified. A novel approach was utilized to select an optimal vaccine composition amongst 15 possible combinations of one to four epitopes to provide maximal binding to a toxic oligomer-enriched low molecular weight fraction of soluble AD brain extract. Results from the preclinical study showed that immunization with a single conformational epitope, peptide 301, the target of the PMN310 antibody, was sufficient to produce maximal reactivity against AD brain oligomers. Title: Novel Approach to Optimization of Alpha-Synuclein Vaccine Composition for Maximal Targeting of Toxic Alpha-Synuclein Species Presenter: Johanne Kaplan, Chief Development Officer, ProMIS Neurosciences Abstract Number: 1310 Vaccination against pathogenic species of alpha-synuclein (ASyn; toxic oligomers, small soluble seeding fibrils), has the potential to protect against synucleinopathies, which include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Vaccine constructs containing computationally-derived conformational B cell epitopes of misfolded pathogenic ASyn were tested in mice. The potential advantage of this approach, as opposed to inducing pan-ASyn reactivity, lies in preserving normal ASyn function and minimizing the diversion of active antibody by the more abundant non-toxic forms of the protein in the blood and central nervous system. Results from the preclinical study showed that vaccination with conformational B cell epitopes produced high affinity antibodies with the desired selectivity for pathogenic ASyn and identified optimal vaccine configurations for further development. Title: Selective Targeting of Pathogenic TDP-43 with Misfolding-Specific Monoclonal Antibodies and Intrabodies Against a Pathogenic Loss-of-Structure Epitope in the Nterminal Domain Presenter: Neil Cashman, MD, Chief Scientific Officer and Co-founder of ProMIS Neurosciences Abstract Number: 1426 TAR DNA-binding protein 43 (TDP-43) is associated with the pathogenesis of ALS, frontotemporal dementia, and AD. Normally, TDP-43 is predominantly localized in the nucleus, and regulates RNA splicing, transport, and stability. In disease, it is mislocalized to the cytoplasm and forms aggregates, which contribute to neurotoxicity and cell-to-cell propagation of pathogenic TDP-43. Development of effective immunotherapeutic agents requires stringent selectivity for misfolded TDP-43 in order to maintain the essential physiological functions of the normal isoform. The study's objective was to generate and evaluate the activity of monoclonal antibodies and intrabodies against an N-terminal domain epitope only exposed when the protein is misfolded in disease. Results of the preclinical study provided proof-of-concept evidence that supports selective targeting of misfolded toxic aggregates of TDP-43 as a potentially safe and effective avenue to treat neurodegenerative diseases associated with TDP-43 proteinopathy. Abstracts are available on the Poster and Publications page of the Company's website at About PMN310 PMN310 is a humanized monoclonal antibody (mAb) designed and developed based on its selectivity for soluble amyloid-beta oligomers, which are believed to be the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, impair synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, PMN310 aims to directly address the growing body of evidence indicating they may be the primary underlying cause of the neurodegenerative process in Alzheimer's disease. PMN310 has successfully completed a Phase 1a clinical study (NCT06105528), a double-blind, placebo-controlled, single ascending dose study of the safety, tolerability and pharmacokinetics of PMN310 infusions in healthy volunteers. About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics and vaccines selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to selectively bind oligomers. PMN310 has successfully completed a Phase 1a clinical study and is dosing Alzheimer's disease patients in a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, 'forward-looking information') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'pleased to', 'look forward to', 'potential to', 'targets', 'expects' or 'does not expect', 'is expected', 'excited about', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company's preclinical data, novel vaccine approach to target toxic oligomers and the potential implications thereof, statements of reference to its preclinical studies and to its lead product, PMN310, designed for the treatment of AD, statements related to the targeting of toxic misfolded proteins in neurodegenerative diseases and the belief that they have greater therapeutic potential due to reduction of off-target activity, management's belief that its patented platform technology has created an antibody candidate specific to toxic misfolded oligomers, and therapeutic activity and preferential targeting of toxic soluble aggregates by Aß-directed antibodies and the potential implications thereof. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that preclinical results or early results may not be indicative of future results, the Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the 'Risk Factors' section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2023 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. For further information: Visit us at Please submit media inquiries to info@ For Investor Relations, please contact: Precision AQ (formerly Stern IR) Anne Marie Fields, Managing Director Tel. 212-362-1200 Sign in to access your portfolio
